How CAR-NK Cells Could Work Better than CAR-T Cells
James Crowley, Professor of Medicine emeritus at Brown University, posted on LinkedIn:
”The major hurdle addressed is donor cell rejection by the recipient’s immune system, which the authors determined is primarily mediated by host CD8+ T cells.
To overcome rejection, the researchers engineered a single gene construct that combines a selective shRNA to knock down rejection-related HLA Class I molecules, a Chimeric Antigen Receptor (CAR) for tumor targeting, and the expression of immune checkpoint ligands like PD-L1 or single-chain HLA-E (SCE).
This integrated approach not only enabled the CAR-NK cells to evade host-mediated rejection in mouse models but also surprisingly enhanced their anti-tumor activity and provided a favorable safety profile by reducing inflammatory cytokines.”

Stay updated with Hemostasis Today.
-
Nov 6, 2026, 22:54Vincenzo De Angelis: Presenting Trends and Challenges in Blood and Plasma Collection and Use in Europe
-
Nov 6, 2026, 22:50Alexis Caulier: Leveraging Epigenetic Silencing in HSCs to Modulate Platelet Aggregation
-
Nov 6, 2026, 22:40Panama Achieves Self-Sufficiency in Haemophilia Care – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Nov 6, 2026, 22:31Luisa Weiss: Exploring the Role of Platelets and Extracellular Vesicles in Calcific Aortic Valve Disease
-
Nov 6, 2026, 22:29Nour Al-Mozain: The Role of Therapeutic Apheresis and Cell Therapy in Advancing Regional Practice
-
Nov 6, 2026, 22:28Moazzam Shahzad: Celebrating Mentees Receiving the 2026 ASH Abstract Achievement Award
-
Nov 6, 2026, 22:25Habib Bennaceur: Self-Sufficiency in Haemophilia Care – A Major Achievement for Panama
-
Nov 6, 2026, 22:25Alessandro Lucchesi: Engineering Disease Trajectories in Myeloproliferative Neoplasms at RiseMPN 2026
-
Nov 6, 2026, 22:24Davood Bava: A New Practical Handbook for Advances in Transfusion Medicine